About Bristol-Myers Squibb Company
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructive HCM. The company also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu to treat moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for the reduction of risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug for multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane to treat breast cancer. Further, the company provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC, as well as NSCLC and pancreatic cancer. It sells its products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. The company has a strategic collaboration with Arcus Biosciences, Inc. to develop a treatment regimen that delivers tumor control in kidney cancer. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.
Bristol-Myers Squibb Company (BMY) is a Healthcare company in the Drug Manufacturers - General industry with a market capitalisation of $130.2B. The stock trades at 14.04x trailing earnings and yields 3.91%.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Market cap
- $130.2B
- P/E ratio
- 14.04
- Forward P/E
- 9.72
- EPS (TTM)
- $4.54
- Revenue (TTM)
- $49.2B
- Free cash flow
- $8.1B
- Profit margin
- 18.9%
- Dividend yield
- 3.91%
- Beta
- 0.23
- Shares outstanding
- 2B
Financial health: Fair7.3/10
7 strengths, 2 concerns. Weakest points: debt to equity, peg ratio.
- Debt to equity: 2.43 (Concern, benchmark < 0.5) — Debt of 2.43x equity is high against the 0.5x benchmark. It has deteriorated over the last 4 years.
- Net debt vs cash flow: 2.7y (Strong, benchmark < 4 years) — Net debt of $34.2B is 2.7x annual free cash flow — about 3 years of cash flow to repay.
- Current ratio: 1.26 (Watch, benchmark > 1.5) — Short-term assets cover 1.26x short-term liabilities, against Graham's 1.5x floor. It has been broadly flat over the last 4 years.
- Return on equity: 46.6% (Strong, benchmark > 15%) — Earns 46.6% on shareholder equity, comfortably past the > 15% mark.
- Gross margin: 71.7% (Strong, benchmark > 40%) — Keeps 71.7% of revenue after the direct cost of sales, comfortably past the > 40% mark.
- Net margin: 18.9% (Strong, benchmark > 10%) — Turns 18.9% of revenue into profit, comfortably past the > 10% mark.
- Free cash flow: $12.8B (Strong, benchmark positive) — Generated $12.8B of free cash flow after capital spending. It has been broadly flat over the last 4 years.
- Revenue growth: 5.7% (Watch, benchmark > 10%) — Revenue changed 5.7% year on year, short of the > 10% mark.
- Earnings growth: 153.1% (Strong, benchmark > 10%) — Earnings changed 153.1% year on year, comfortably past the > 10% mark.
- PEG ratio: 2.41 (Concern, benchmark < 1) — At 2.41, the price looks expensive relative to expected growth — Lynch treated 1.0 as fair value.
- Payout ratio: 55.3% (Strong, benchmark < 60%) — Pays out 55.3% of earnings as dividends, leaving room to keep paying.